Vertex Is The First To Get NaV1.8 To Proof Of Concept For Pain
Effort Is Built On Decades Of Sodium Channel Research
Chief scientific officer David Altshuler talked to Scrip about the late-stage development plan for a drug that could represent a blockbuster-sized commercial opportunity, after two Phase II studies testing VX-548 met their primary endpoints.
You may also be interested in...
Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.
The US firm has received the FDA thumbs-up to continue a trial for its novel cell therapy candidate, VX-880, after what was perceived in some circles as an over-cautious decision by the regulator to pause the study in March.
Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.